Kynam Capital Management, LP
PRINCETON, NJ · CIK 1907884 · 13F filing filed 2022-08-15
SEC-registered investment adviser since 2022 · limited partnership
- Assets managed$2.4bn
- Staff3 · 2 in investment roles
- Main clients (by assets)Private funds 100%
- Private funds1 (1 hedge) · $2.4bn gross assets
- Form ADV · 2026-04-10SEC adviser record
- Legal entityKYNAM CAPITAL MANAGEMENT, LP (US)
- Kindhedge funds, futures
- Others nearbyPrinceton, NJ
As an employer
- Private fundshedge 1
$387.6m
reported value
+26.0% vs Q1 2022
31positions
79.4%in top 10
3 new
17 added
11 reduced
3 sold out
vs Q1 2022
Options: 1 call positions ($2.5m notional), 2 put positions ($1.5m notional) – listed below, not included above.
Holdings, Q2 2022
The small lines show how much was held over the last 4 quarters (adjusted for stock splits).
| Security | Value | Change |
|---|---|---|
| GLOBAL BLOOD THERAPEUTICS IN GBT | $70.3m18.13% | Added +860.7k |
| SYNDAX PHARMACEUTICALS INC SNDX | $48.3m12.47% | Added +579.4k |
| NATERA INC NTRA | $43.9m11.33% | Added +272.6k |
| CELLDEX THERAPEUTICS INC NEW CLDX | $30.5m7.88% | Added +379.2k |
| TRAVERE THERAPEUTICS INC TVTX | $29.9m7.72% | Added +364.2k |
| VERA THERAPEUTICS INC VERA | $20.7m5.35% | Added +1.0m |
| GOSSAMER BIO INC GOSS | $19.7m5.08% | Added +517.7k |
| BIOGEN INC BIIB | $16.1m4.15% | Added +40.7k |
| VAXCYTE INC PCVX | $15.7m4.06% | Added +144.1k |
| BURNING ROCK BIOTECH LTD SPONSORED ADS | $12.5m3.23% | Added +3.5m |
| BIOCRYST PHARMACEUTICALS INC BCRX | $9.9m2.56% | New |
| AMICUS THERAPEUTICS INC FOLD | $9.7m2.49% | Added +326.5k |
| COGENT BIOSCIENCES INC COGT | $9.0m2.33% | New |
| VIRIDIAN THERAPEUTICS INC VRDN | $6.8m1.76% | Added +317 |
| LIQUIDIA CORPORATION LQDA | $6.5m1.69% | Added +341.0k |
| AMARIN CORP PLC SPONS ADR NEW | $6.0m1.54% | Added +1.7m |
| WAVE LIFE SCIENCES LTD 96663EUR | $5.5m1.42% | Reduced -215.0k |
| XENON PHARMACEUTICALS INC XENE | $5.3m1.37% | Reduced -308.3k |
| CONCERT PHARMACEUTICALS INC CNCE | $4.2m1.09% | New |
| CENTESSA PHARMACEUTICALS PLC SPONSORED ADS | $3.7m0.95% | Added +88.7k |
| MERUS N V MRUS | $2.3m0.61% | Reduced -13.1k |
| FATE THERAPEUTICS INC FATE | $2.0m0.52% | Reduced -10.3k |
| AFFIMED N V COM | $1.9m0.50% | Added +353.1k |
| AKOUOS INC COM | $1.8m0.46% | Reduced -4.1k |
| PUMA BIOTECHNOLOGY INC PBYI | $1.7m0.43% | Reduced -73.5k |
| OLEMA PHARMACEUTICALS INC OLMA | $1.0m0.26% | Reduced -31.6k |
| SERES THERAPEUTICS INC COM | $887.0k0.23% | Reduced -32.8k |
| CONNECT BIOPHARMA HLDGS LTD ADS | $643.0k0.17% | Added +511.9k |
| CABALETTA BIO INC CABA | $580.0k0.15% | Reduced -69.3k |
| CATALYST BIOSCIENCES INC COM NEW | $166.0k0.04% | Reduced -12.7k |
| NEOLEUKIN THERAPEUTICS INC COM | $128.0k0.03% | Reduced -15.8k |
Sold out since Q1 2022
| Security | Value then |
|---|---|
| SIERRA ONCOLOGY INC | $6.2m193.3k shares |
| RADIUS HEALTH INC RDUS | $1.6m185.5k shares |
| KRYSTAL BIOTECH INC KRYS | $1.2m18.4k shares |
Options (notional value)
| Underlying | Notional | Change |
|---|---|---|
| CELLDEX THERAPEUTICS INC NEW CLDX · Call | $2.5m246.4k shares | New |
| ALNYLAM PHARMACEUTICALS INC ALNY · Put | $925.0k50.0k shares | New |
| KARUNA THERAPEUTICS INC Put | $578.0k38.9k shares | New |
Stakes above 5%
Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.
| Company | Stake |
|---|---|
| BURNING ROCK BIOTECH LTD 13G · filed 2026-05-15 | 14.0% |
| SYNDAX PHARMACEUTICALS INC SNDX · 13G · filed 2025-02-14 | 10.0%≈ $186.2m |
| CYTOMX THERAPEUTICS INC CTMX · 13G · filed 2026-08-14 | 10.0% |
| CELLDEX THERAPEUTICS INC NEW CLDX · 13G · filed 2026-08-14 | 6.8% |
| VIRIDIAN THERAPEUTICS INC VRDN · 13G · filed 2026-08-14 | 5.7% |
| SUTRO BIOPHARMA INC 13G · filed 2026-05-15 | 5.3% |
| CULLINAN THERAPEUTICS INC CGEM · 13G · filed 2026-03-04 | 5.3%≈ $56.7m |